With the market so volatile right now, there are plenty of savvy opportunities to be found. The key is to look for strong stocks that have been unfairly discounted by the market. We used TipRanks’ Top Analyst Stocks tool to pinpoint three key stocks that are poised to soar from current levels. These are under-performing stocks with substantial backing from Wall Street’s best-performing analysts. And as you will see below, all three of these stocks have big upside potential ahead. Let’s take a closer look now:

Global Blood Therapeutics (NASDAQ:GBT)

GBT specializes in sickle cell disease, an inherited blood disorder caused by a genetic mutation. However, the stock plunged nearly 17% on June 15 following mixed results from a critical trial. Shares have slightly improved since then, but on a one-month basis, GBT is still trading down over 10%.

The trial in question was a HOPE-KIDS 1 Phase 2a study. GBT was testing how children with sickle cell disease reacted to experimental drug voxelotor. While the hemoglobin response was impressive, the total symptom score (TSS) came in below expectations. But the drug candidate remains attractive, according to top-ranked Wedbush analyst Liana Moussatos.

“Barring any dramatic deterioration in the safety profile, we believe voxelotor remains an eminently approvable medicine with clear disease modifying properties directed at a population with limited clinical options,” writes Moussatos. She reiterated her $70 price target on GBT (66% upside potential), while adding “we remain byers on weakness.”

Indeed, from an investing perspective, the stock only appears more attractive post-plunge: “With the June 15, 2018, drawdown in the rearview, Global Blood’s stock is now underperforming the sector, up modestly 1.5% YTD vs. roughly 15% for the XBI; offering significantly better risk-reward heading into the HOPE Part A readout, in our view.”

Our data shows that the Street is united in its bullish take on GBT. The stock floats a ‘Strong Buy’ analyst consensus rating with 8 consecutive recent buy ratings. Meanwhile, the average analyst price target of $73.71 indicates huge upside potential of 75%.

Alarmcom (NASDAQ:ALRM)

As the name suggests, Alarmcom uses tech to keep homes safer and more connected. Over five million people use ALRM as a security system. And the company also has smart home systems covered with multiple interconnected devices from energy management to full home automation.

The stock sunk 17% on June 20 and 21 following a rating downgrade from Goldman Sachs analyst Gabriela Borges. She also slashed her price target to $37 from $41. This suggests a 2% downside from the current share price. Borges believes there is a risk to Alarmcom from cheaper do-it-yourself options instead of using professionally installed monitoring systems.

Interestingly, however, our data reveals that Borges significantly underperforms the average analyst. On a one-year basis she is currently tracking only a 52% success rate and -0.2% average return:

And at the same time, the rest of the Street has a bullish outlook on Alarmcom. Indeed, if we focus in on only ratings from top-ranked analysts Alarmcom actually has a ‘Strong Buy’ analyst consensus rating. This comes with an average price target of $54 (44% upside potential).

Most notably, five-star Maxim Group analyst Nehal Chokshi has a Buy rating on ALRM with a $59 price target (57% upside potential). He refers to a number of recently launched catalysts that make current guidance look conservative.

These catalysts center around big growth in the more lucrative Alarmcom commercial subscribers (who currently represent only ~2.5% of Alarmcom core subscribers). Alarmcom has just launched; (1) the first official Alarmcom commercial offering; (2) smarter access control for businesses; and (3) new and improved commercial-grade video products and image sensors. With all this in mind he sees ALRM subscriber base growth surging from a 39% market share gain in CY15 to 47% in CY29-so brace yourself for growth!

Micron (NASDAQ:MU)

Hot chip stock Micron is just out with its fiscal third quarter results. The good news: the results easily beat expectations. Micron reported fiscal third-quarter earnings of $3.10 a share, on sales of $7.8 billion, up from $5.57 billion in the year-ago quarter. The even better news: share prices are marginally down (by 2% on a five-day basis, and 7.2% on a one-month basis). This means the stock is still trading at a very compelling $59.

If we turn to the Street, the outlook is particularly bullish from top analysts. While analysts in general have a Moderate Buy MU consensus rating, the sentiment shifts to ‘Strong Buy’ if we only look at ratings from best-performing analysts. Indeed, these top analysts believe share prices can spike 41% to hit $80.52. You can click on the graph below for further insight into these ratings:

Top 100 Stifel Nicolaus Kevin Cassidy has just boosted his price target from $106 to $108 (89% upside potential). He believes the ‘beat and raise’ quarter proves that the memory cycle is nowhere near its cyclical peak. Instead a number of growth drivers are keeping demand in place, from widening memory applications to the increasing importance of memory in system performance.

Similarly, Needham analyst Rajvindra Gill has just reiterated his Strong Buy MU rating. He has a $100 price target on MU (75% upside potential from current levels). The Street is still discounting the structural changes in the memory industry, argues Gill. “This is evident in MU’ 65% DRAM GM. On the NAND side, Micron is strategically expanding into managed NAND solutions where ASPs [average selling prices] are higher.”

Plus, he notes that this is combined with a commitment to return 50% free cash flow starting in FY19 in stock buybacks and an aggressive de-leveraging campaign. The conclusion “we see earnings power of $12-$13, and continue to advocate for the name at these levels.”